Skip to content

Humacyte, Inc.

HUMA· NasdaqCore metricsCIK 1818382

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · +0.34%
Market cap
$165.54M
277.8M shares
Filings
506
$1.03M
Q3 2026
-$15.54M
Q3 2026N/M FY25 yoy
-$23.52M
Q3 2026N/M FY25 yoy
-$62.42M
Q3 2026derivedN/M FY25 yoy
-$0.06
Q3 2026N/M FY25 yoy
$64.52M
Q3 2026+12.4% FY25 yoy
$165.54M
—
69.1×
9.2×
-53.51%
—

Twelve months to Sep 30, 2026 · derived

Price

$0.595953.45%$0.6841past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$2.04MFY 2025
$2.04M0FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$2,038,000reported
FY 20242024-12-31$0reported

Segments

Products
Revenue by Products, FY2024 to FY2025FY2024FY2025Product · FY2025 · $1.39MContract Revenue · FY2025 · $649.00K
LineFY2025ShareChange
Product$1.39M68%—
Contract Revenue$649.00K32%—
Total$2.04M

From the 10-K filed Mar 27, 2026HUMA

Biological products, except diagnostic substances

Humacyte, Inc. is the 75th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Humacyte, Inc. · CIK 1818382 · Engraved from SEC EDGAR